Merck enlists Astex to search for p53 cancer drug in expanded deal
Merck has expanded its oncology collaboration with Otsuka subsidiary Astex Pharmaceuticals to the tune of a $35 million upfront payment and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
